iSpecimen (ISPC) EBIT (2020 - 2026)

iSpecimen's EBIT history runs 7 years deep, the most recent figure standing at -$2.5 million for Q1 2026.

• In Q1 2026, EBIT fell 54.93% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at -$9.9 million (up 13.09% YoY), while the FY2025 annual figure was -$9.0 million, up 29.46% from the prior year.
• EBIT was -$2.5 million for Q1 2026 at iSpecimen, up from -$2.7 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$1.6 million in Q1 2025 to a low of -$5.8 million in Q4 2024.
• Historically, EBIT has averaged -$2.7 million across 5 years, with a median of -$2.5 million in 2023.
• The sharpest annual moves came in 2022 and 2025: EBIT tumbled 150.19% in 2022, then surged 53.98% in 2025.
• A 5-year view of EBIT shows it stood at -$2.1 million in 2022, then slumped by 34.06% to -$2.9 million in 2023, then sank by 103.43% to -$5.8 million in 2024, then soared by 53.98% to -$2.7 million in 2025, then increased by 5.56% to -$2.5 million in 2026.
• The last three EBIT figures came in at -$2.5 million (Q1 2026), -$2.7 million (Q4 2025), and -$2.8 million (Q3 2025), per Business Quant data.